Roth Mkm Reiterates Buy Rating for Bio-Path (NASDAQ:BPTH)

Roth Mkm reaffirmed their buy rating on shares of Bio-Path (NASDAQ:BPTH) in a report released on Thursday, Benzinga reports. Roth Mkm currently has a $40.00 target price on the stock.

Separately, StockNews.com initiated coverage on Bio-Path in a research report on Tuesday, April 16th. They set a sell rating on the stock.

Bio-Path Stock Performance

Shares of Bio-Path stock opened at $4.29 on Thursday. Bio-Path has a one year low of $2.70 and a one year high of $44.80. The company has a market cap of $2.92 million, a price-to-earnings ratio of -0.11 and a beta of 0.35. The business’s 50 day moving average price is $5.40 and its 200 day moving average price is $8.52.

Bio-Path (NASDAQ:BPTH) last announced its quarterly earnings data on Friday, March 8th. The company reported ($5.40) EPS for the quarter, hitting analysts’ consensus estimates of ($5.40). During the same period in the previous year, the company posted ($10.60) EPS. On average, analysts predict that Bio-Path will post -18.71 EPS for the current fiscal year.

Institutional Investors Weigh In On Bio-Path

A number of institutional investors and hedge funds have recently added to or reduced their stakes in BPTH. Citadel Advisors LLC purchased a new stake in Bio-Path in the third quarter valued at $35,000. Virtu Financial LLC purchased a new stake in Bio-Path in the first quarter valued at $38,000. Renaissance Technologies LLC purchased a new stake in Bio-Path in the second quarter valued at $70,000. Walleye Capital LLC purchased a new stake in Bio-Path in the third quarter valued at $77,000. Finally, Vanguard Group Inc. raised its position in Bio-Path by 77.5% in the fourth quarter. Vanguard Group Inc. now owns 270,029 shares of the company’s stock valued at $125,000 after purchasing an additional 117,914 shares during the period. Hedge funds and other institutional investors own 5.74% of the company’s stock.

Bio-Path Company Profile

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.